Axogen, Inc. (AXGN)

Market Cap	1.09B
Revenue (ttm)	214.71M
Net Income (ttm)	-2.10M
Shares Out	46.12M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	385.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	989,370
Open	23.99
Previous Close	23.99
Day's Range	23.21 - 24.17
52-Week Range	9.22 - 24.25
Beta	1.09
Analysts	Strong Buy
Price Target	27.71 (+17.57%)
Earnings Date	Oct 29, 2025

About AXGN

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Michael Dale
• Employees: 452
• Stock Exchange: NASDAQ
• Ticker Symbol: AXGN
• Website: https://www.axogeninc.com

Financial Performance

In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $27.71, which is an increase of 17.57% from the latest price.

Price Target

$27.71

(17.57% upside)

Analyst Consensus: Strong Buy